AGA Medical Holdings, Inc. Announces Pricing of its Initial Public Offering.MINNEAPOLIS -- AGA Medical Holdings, Inc. (the "Company") announced the pricing of its initial public offering of 13,750,000 shares of common stock at $14.50 per share. The Company expects to sell 6,509,000 shares, and 7,241,000 shares are expected to be sold by the selling stockholders. The offering is expected to close on October 26, 2009. The common stock of the Company will be listed on the Nasdaq Global Select Market and will trade under the symbol "AGAM AGAM Ambiente Gas Acqua Monza SpA (Italian) ." The underwriters have a 30-day option to purchase up to an additional 2,062,500 shares of common stock from the Company to cover overallotments, if any. BofA Merrill Lynch, Citi, Deutsche Bank Securities, Leerink Swann and Wells Fargo Securities have acted as joint book-running managers for the offering. A copy of the final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. relating to these securities may be obtained, when available, from: Merrill Lynch, Pierce, Fenner & Smith Incorporated, 4 World Financial Center, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 10080, Attention: Preliminary Prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders Department or by calling 1-866-500-5408; Citigroup Global Markets Inc., Brooklyn Army Terminal The Brooklyn Army Terminal consists of large complex of piers, docks, warehouses, cranes, railroad sidings and cargo loading equipment. The terminal was responsible for shipment of army equipment and personnel overseas. , 140 58th Street, 8th Floor, Brooklyn, New York 11220 or by calling 1-800-831-9146; Deutsche Bank Securities Inc., 100 Plaza One, Floor 2, Jersey City, New Jersey 07311-3901 or by calling 1-800-503-4611; Leerink Swann LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by calling 1-800-808-7525, Ext. 4814; or Wells Fargo Securities, LLC, Attn: Equity Syndicate Dept., 375 Park Avenue, New York, NY 10152 or by calling 1-800-326-5897. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About AGA Medical Holdings, Inc. AGA Medical Holdings, Inc., based in Plymouth, Minn., is a leading innovator and manufacturer of medical devices for the treatment of structural heart defects and vascular diseases. Founded in 1995 by Dr. Kurt Amplatz, a former University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. professor and researcher, AGA Medical's range of AMPLATZER[R] products help improve patient outcomes, reduce length of hospital stay and accelerate patient recovery times. AMPLATZER products significantly advanced the treatment of the most common congenital "holes in the heart," such as atrial septal defects, patent foramen ovale patent foramen ovale PFO Cardiology An opening between the left and right atria which allows blood to bypass the lungs in utero; the FO normally closes shortly after birth, but remains open in up to 20%; a PFO is, in absence of other cardiac defects, is of no consequence and ventricular septal defects. More than 1,500 peer-reviewed articles supporting the benefits of AMPLATZER products have been published in medical literature. AGA Medical markets AMPLATZER products in 112 countries worldwide. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion